CN101020688A - 1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉衍生物、制备方法和用途 - Google Patents
1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉衍生物、制备方法和用途 Download PDFInfo
- Publication number
- CN101020688A CN101020688A CN 200710038006 CN200710038006A CN101020688A CN 101020688 A CN101020688 A CN 101020688A CN 200710038006 CN200710038006 CN 200710038006 CN 200710038006 A CN200710038006 A CN 200710038006A CN 101020688 A CN101020688 A CN 101020688A
- Authority
- CN
- China
- Prior art keywords
- carboline
- indolyl
- tetrahydro
- compound
- derivative according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ZWNGOYWZUZEHQG-UHFFFAOYSA-N 1-(1h-indol-3-yl)-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole Chemical class C1=CC=C2C(C3C4=C(C5=CC=CC=C5N4)CCN3)=CNC2=C1 ZWNGOYWZUZEHQG-UHFFFAOYSA-N 0.000 title claims abstract description 87
- 238000002360 preparation method Methods 0.000 claims abstract description 60
- 150000001875 compounds Chemical class 0.000 claims abstract description 41
- 239000003814 drug Substances 0.000 claims abstract description 17
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 10
- 229940121375 antifungal agent Drugs 0.000 claims abstract description 9
- -1 cinnamoyl Chemical group 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 29
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 16
- OLNJUISKUQQNIM-UHFFFAOYSA-N indole-3-carbaldehyde Chemical compound C1=CC=C2C(C=O)=CNC2=C1 OLNJUISKUQQNIM-UHFFFAOYSA-N 0.000 claims description 13
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 claims description 10
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 8
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 8
- 241001330975 Magnaporthe oryzae Species 0.000 claims description 6
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 claims description 5
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims description 5
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 claims description 5
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims description 5
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 claims description 5
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 claims description 5
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 claims description 5
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 claims description 5
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 claims description 5
- 229940126657 Compound 17 Drugs 0.000 claims description 5
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 claims description 5
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims description 5
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 claims description 5
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 claims description 5
- 229940125904 compound 1 Drugs 0.000 claims description 5
- 229940125773 compound 10 Drugs 0.000 claims description 5
- 229940125797 compound 12 Drugs 0.000 claims description 5
- 229940126543 compound 14 Drugs 0.000 claims description 5
- 229940125758 compound 15 Drugs 0.000 claims description 5
- 229940126142 compound 16 Drugs 0.000 claims description 5
- 229940125810 compound 20 Drugs 0.000 claims description 5
- 229940126086 compound 21 Drugs 0.000 claims description 5
- 229940126208 compound 22 Drugs 0.000 claims description 5
- 229940125833 compound 23 Drugs 0.000 claims description 5
- 229940125961 compound 24 Drugs 0.000 claims description 5
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims description 5
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims description 5
- 229940125782 compound 2 Drugs 0.000 claims description 4
- 229940126214 compound 3 Drugs 0.000 claims description 4
- 229940125898 compound 5 Drugs 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 150000001263 acyl chlorides Chemical class 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000003429 antifungal agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 30
- 238000003786 synthesis reaction Methods 0.000 abstract description 30
- 230000000843 anti-fungal effect Effects 0.000 abstract description 9
- 238000002474 experimental method Methods 0.000 abstract description 4
- 240000007594 Oryza sativa Species 0.000 abstract description 3
- 235000007164 Oryza sativa Nutrition 0.000 abstract description 3
- 235000009566 rice Nutrition 0.000 abstract description 3
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical class [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 36
- 238000005160 1H NMR spectroscopy Methods 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 14
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- GFAUNYMRSKVDJL-UHFFFAOYSA-N formyl chloride Chemical compound ClC=O GFAUNYMRSKVDJL-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- MVARAGCLLOCBJZ-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-1-carbaldehyde Chemical compound C(=O)C1NCCC=2C3=CC=CC=C3NC1=2 MVARAGCLLOCBJZ-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- OGIMCDMIYGVEHU-UHFFFAOYSA-N 1-(1h-indol-3-yl)-9h-pyrido[3,4-b]indole Chemical compound C12=CC=CC=C2NC2=C1C=CN=C2C1=CNC2=CC=CC=C21 OGIMCDMIYGVEHU-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000005918 in vitro anti-tumor Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- WOGITNXCNOTRLK-VOTSOKGWSA-N (e)-3-phenylprop-2-enoyl chloride Chemical compound ClC(=O)\C=C\C1=CC=CC=C1 WOGITNXCNOTRLK-VOTSOKGWSA-N 0.000 description 2
- PBLNBZIONSLZBU-UHFFFAOYSA-N 1-bromododecane Chemical compound CCCCCCCCCCCCBr PBLNBZIONSLZBU-UHFFFAOYSA-N 0.000 description 2
- LSXKDWGTSHCFPP-UHFFFAOYSA-N 1-bromoheptane Chemical compound CCCCCCCBr LSXKDWGTSHCFPP-UHFFFAOYSA-N 0.000 description 2
- VMKOFRJSULQZRM-UHFFFAOYSA-N 1-bromooctane Chemical compound CCCCCCCCBr VMKOFRJSULQZRM-UHFFFAOYSA-N 0.000 description 2
- CFTOTSJVQRFXOF-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Chemical class N1C2=CC=CC=C2C2=C1CNCC2 CFTOTSJVQRFXOF-UHFFFAOYSA-N 0.000 description 2
- RNQKFVUQTYKTMI-UHFFFAOYSA-N 2-(1h-indol-3-yl)-n-(1h-indol-3-ylmethyl)ethanamine Chemical compound C1=CC=C2C(CNCCC=3C4=CC=CC=C4NC=3)=CNC2=C1 RNQKFVUQTYKTMI-UHFFFAOYSA-N 0.000 description 2
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 2
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 2
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 2
- SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 2
- KAZRCBVXUOCTIO-UHFFFAOYSA-N 5-(chloromethyl)furan-2-carbaldehyde Chemical compound ClCC1=CC=C(C=O)O1 KAZRCBVXUOCTIO-UHFFFAOYSA-N 0.000 description 2
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 2
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 2
- 241001344131 Magnaporthe grisea Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 2
- 229940073608 benzyl chloride Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
- KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 229960002867 griseofulvin Drugs 0.000 description 2
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000004763 spore germination Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- XZBXAYCCBFTQHH-UHFFFAOYSA-N 3-chloropropylbenzene Chemical compound ClCCCC1=CC=CC=C1 XZBXAYCCBFTQHH-UHFFFAOYSA-N 0.000 description 1
- MFEILWXBDBCWKF-UHFFFAOYSA-N 3-phenylpropanoyl chloride Chemical compound ClC(=O)CCC1=CC=CC=C1 MFEILWXBDBCWKF-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000037026 Invasive Fungal Infections Diseases 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 125000006355 carbonyl methylene group Chemical group [H]C([H])([*:2])C([*:1])=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- XBPOBCXHALHJFP-UHFFFAOYSA-N ethyl 4-bromobutanoate Chemical compound CCOC(=O)CCCBr XBPOBCXHALHJFP-UHFFFAOYSA-N 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明属药物合成领域,涉及通式(I)的2位有各种烃基或酰基取代的1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉化合物及其类似物及其制备方法和在医学上的应用。本发明所述的化合物经初步药效学研究,通过体外抗稻瘟霉菌实验和体外抗肿瘤实验,结果显示,具有良好的抗真菌和抗肿瘤活性,可研制开发为新型抗真菌药物和抗肿瘤药物。
Description
技术领域
本发明属药物合成领域,涉及1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉衍生物,制备方法和应用。具体涉及一种2位有各种烃基或酰基取代的1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉衍生物,及其制备方法和在医学上的应用。
背景技术
抗生素的出现开辟了医疗革命的新时代,然而随着抗生素在全球的普及和滥用,无论革兰氏阳性菌或阴性菌均已出现耐药趋向,其中,革兰氏阳性细菌的耐药问题尤为严重。据报道,一些非致病菌成为条件致病菌,如变形杆菌、绿脓杆菌等;病毒与深部真菌等感染仍然缺乏良好的防治药物。而且随着抗肿瘤药、免疫抑制剂等的广泛应用,器官移植的大量开展以及艾滋病的流行,急性侵袭性真菌感染(IFI)的发病率呈现逐渐升高的趋势。这些情况的出现,迫切要求新型抗菌药物的问世,并对已有的抗菌药物发展策略提出了挑战。世界范围的许多制药公司都在积极寻找能对付耐药菌的新型药物,以及继续寻找抗真菌药物的先导化合物,对于开发广谱、高效、低毒的抗真菌药物具有实际意义。
据不完全统计,全世界每年约有2000万的新发恶性肿瘤病例;我国每年的新发病例约为160-200万,死亡数约130万。由于肿瘤早期具有转移的能力,临床诊断原发肿瘤中约50%的患者已产生远位转移,肿瘤细胞增长快、易变异,从而易产生多药耐药,导致化疗失败,据有关统计,其中90%以上与肿瘤细胞的多药耐药相关,目前临床上应用的抗肿瘤药物远不能满足治疗的要求。
1-(3-吲哚基)-β-咔啉(Eudistomin U)已被证实具有良好的抗肿瘤活性。许多天然的四氢-β-咔啉衍生物具有广泛的生物活性,例如抗真菌和抗肿瘤活性等。
发明内容:
本发明的目的是提供新型四氢-β-咔啉类化合物,具体涉及一种2位有各种烃基或酰基取代的1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉化合物及其类似物。
本发明的另一目的是提供上述2位有烃基、酰基取代的1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉衍生物的制备方法。
本发明新型1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉衍生物具有下述通式(I)的结构:
其中
或R=丙酰基,肉桂酰基,3-吲哚甲酰基,甲烷磺酰基,对甲苯磺酰基,苄基,5-(2-甲酰基呋喃基)亚甲基,乙氧羰基亚甲基,乙氧羰基正丙基);或R=(CH2)mCH3(m=1~11)。
本发明所述的1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉化合物通过下述方法制备:采用吲哚为原料经酰化得吲哚-3-甲醛,与色胺经缩合、环合得到1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与各种酰氯酰化后或与各种卤代物烃化后得到相应的化合物。其中,与各种酰氯酰化后得到相应的化合物1-14;与各种卤代物烃化后得到相应的化合物15-24。
本发明上述化合物经初步药效学研究,通过体外抗稻瘟霉菌实验和体外抗肿瘤实验,其中部分化合物显示了良好的活性,具有良好的抗真菌和抗肿瘤活性,可研制开发为新型抗真菌药物和抗肿瘤药物。
本发明的优选化合物具有下述化合物1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24的结构:
本发明化合物1的制备过程如下:
化合物1的制备工艺包括:
吲哚经酰化得吲哚-3-甲醛,与色胺经缩合、环合得到1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与苯甲酰氯酰化后得到1-(3-吲哚基)-2-苯甲酰基-1,2,3,4-四氢-β-咔啉(化合物1)。
本发明化合物2的制备过程如下:
化合物2的制备工艺包括:1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与邻氯苯甲酰氯酰化后得到1-(3-吲哚基)-2-邻氯苯甲酰基-1,2,3,4-四氢-β-咔啉(化合物2)。
本发明化合物3的制备过程如下:
化合物3制备工艺包括:1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与对氯苯甲酰氯酰化后得到1-(3-吲哚基)-2-对氯苯甲酰基-1,2,3,4-四氢-β-咔啉(化合物3)。
本发明化合物4的制备过程如下:
化合物4的制备工艺包括:1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与对硝基苯甲酰氯酰化后得到1-(3-吲哚基)-2-对硝基苯甲酰基-1,2,3,4-四氢-β-咔啉(化合物4)。
本发明化合物5的制备过程如下:
化合物5制备工艺包括:1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与对甲氧基苯甲酰氯酰化后得到1-(3-吲哚基)-2-对甲氧基苯甲酰基-1,2,3,4-四氢-β-咔啉(化合物5)。
本发明化合物6的制备过程如下:
化合物6制备工艺包括:1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与3-吲哚苯甲酰氯酰化后得到1-(3-吲哚基)-2-(3-吲哚)甲酰基-1,2,3,4-四氢-β-咔啉(化合物6)。
本发明化合物7的制备过程如下:
化合物7制备工艺包括:1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与3-吡啶甲酰氯酰化后得到1-(3-吲哚基)-2-(3-吡啶)甲酰基-1,2,3,4-四氢-β-咔啉(化合物7)。
本发明化合物8的制备过程如下:
化合物8制备工艺包括:1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与4-吡啶甲酰氯酰化后得到1-(3-吲哚基)-2-(4-吡啶)甲酰基-1,2,3,4-四氢-β-咔啉(化合物8)。
本发明化合物9的制备过程如下:
化合物9的制备工艺包括:1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与2-吡啶甲酰氯酰化后得到1-(3-吲哚基)-2-(2-吡啶)甲酰基-1,2,3,4-四氢-β-咔啉(化合物9)。
本发明化合物10的制备过程如下:
化合物10制备工艺包括:1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与苯乙酰氯酰化后得到1-(3-吲哚基)-2-苯乙酰基-1,2,3,4-四氢-β-咔啉(化合物10)。
本发明化合物11的制备过程如下:
化合物11的制备工艺包括:1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与苯丙酰氯酰化后得到1-(3-吲哚基)-2-苯丙酰基-1,2,3,4-四氢-β-咔啉(化合物11)。
本发明化合物12的制备过程如下:
化合物12制备工艺包括:1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与肉桂酰氯酰化后得到1-(3-吲哚基)-2-肉桂酰基-1,2,3,4-四氢-β-咔啉(化合物12)。
本发明化合物13的制备过程如下:
化合物13制备工艺包括:1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与甲烷磺酰氯酰化后得到1-(3-吲哚基)-2-甲烷磺酰基-1,2,3,4-四氢-β-咔啉(化合物13)。
本发明化合物14的制备过程如下:
化合物14制备工艺包括:1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与对甲苯磺酰氯酰化后得到1-(3-吲哚基)-2-对甲苯磺酰基-1,2,3,4-四氢-β-咔啉(化合物14)。
本发明化合物15的制备过程如下:
化合物15制备工艺包括:1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与溴乙烷烃化后得到1-(3-吲哚基)-2-乙基-1,2,3,4-四氢-β-咔啉(化合物15)。
本发明化合物16的制备过程如下:
化合物16的制备工艺包括:1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与1-碘代正丙烷烃化后得到1-(3-吲哚基)-2-正丙基-1,2,3,4-四氢-β-咔啉(化合物16)。
本发明化合物17的制备过程如下:
化合物17的制备工艺包括:1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与1-碘代正丁烷烃化后得到1-(3-吲哚基)-2-正丁基-1,2,3,4-四氢-β-咔啉(化合物17)。
本发明化合物18的制备过程如下:
化合物18制备工艺包括:1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与1-溴代正庚烷烃化后得到1-(3-吲哚基)-2-正庚基-1,2,3,4-四氢-β-咔啉(化合物18)。
本发明化合物19的制备过程如下:
化合物19的制备工艺包括:1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与1-溴代正辛烷烃化后得到1-(3-吲哚基)-2-正辛基-1,2,3,4-四氢-β-咔啉(化合物19)。
本发明化合物20的制备过程如下:
化合物20的制备工艺包括:1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与1-溴代正十二烷烃化后得到1-(3-吲哚基)-2-正十二烷基-1,2,3,4-四氢-β-咔啉(化合物20)。
本发明化合物21的制备过程如下:
化合物21制备工艺包括:1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与氯苄烃化后得到1-(3-吲哚基)-2-苄基-1,2,3,4-四氢-β-咔啉(化合物21)。
本发明化合物22的制备过程如下:
化合物22制备工艺包括:1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与5-氯甲基呋喃-2-甲醛烃化后得到1-(3-吲哚基)-2-(5-(2-甲酰基)呋喃)亚甲基-1,2,3,4-四氢-β-咔啉(化合物22)。
本发明化合物23的制备过程如下:
化合物23制备工艺包括:1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与溴乙酸乙酯烃化后得到1-(3-吲哚基)-2-乙氧羰基亚甲基-1,2,3,4-四氢-β-咔啉(化合物23)。
本发明化合物24的制备过程如下:
化合物24的制备工艺包括:1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与4-溴丁酸乙酯烃化后得到1-(3-吲哚基)-2-乙氧羰基丙基-1,2,3,4-四氢-β-咔啉(化合物24)。
本发明所涉及的2位有各种烃基或酰基取代的1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉衍生物,通过初步药效学研究(稻瘟霉菌活性测试和体外抗肿瘤细胞测试),结果显示这类化合物具有抗稻瘟霉菌和体外抗肿瘤细胞活性,可以进一步研制开发为抗真菌药物和抗肿瘤药物。
具体实施方式:
实施例1:合成化合物1,1-(3-吲哚基)-2-苯甲酰基-1,2,3,4-四氢-β-咔啉1)吲哚-3-甲醛的制备
将56ml DMF投入500ml三颈烧瓶中,在冰盐浴中搅拌,保持温度不超过0℃,滴加17.4ml(0.186mol)氧氯化磷。然后再缓慢滴加含20g(0.171mol)吲哚的20ml DMF溶液,在1小时内滴完。滴加完毕后,保持反应液温度35℃反应1.5小时。在冰水浴冷却下,加入80ml冰水,再缓慢加入含80g氢氧化钠的200ml水溶液(先缓慢加入1/3量,剩余的一次性加入),加热回流15分钟,冷却后置冰箱中静置4小时。抽滤,滤饼用大量水洗,抽干后,置红外灯下干燥。得23.0g淡黄色粉末,收率92.8%。熔点:195-196℃。
2)N-(3-吲哚次甲基)-色胺的制备
在100ml圆底烧瓶中加入1.1g(6.8mmol)色胺、0.9g(6.2mmol)吲哚-3-甲醛、60ml苯,加上分水器和冷凝管,氮气保护下加热回流2小时,分去水。TLC显示原料反应完全。蒸去大部分溶剂,冷至室温后析出大量固体,抽滤,固体用少量苯洗涤。真空干燥后得浅黄色固体1.7g,收率:94.8%。熔点:146-148℃。
3)1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉的制备
在50ml圆底烧瓶中加入0.7g(2.4mmol)N-(3-吲哚次甲基)-色胺、5ml氯仿,冰浴冷却下滴加三氟醋酸的氯仿溶液(1.96ml TFA溶于4mlCHCl3),氮气保护下室温搅拌22小时。停止反应,加入15ml乙酸乙酯稀释后用10%碳酸钠水溶液调节pH值9~10,分液,水相用乙酸乙酯提取,合并有机相,饱和氯化钠水溶液(20ml×1)洗涤,有机相用无水硫酸镁干燥过夜,过滤,蒸干滤液,得0.66g固体。经硅胶柱层析后得0.4g浅黄色固体,收率:58%。熔点:142-144℃。
4)1-(3-吲哚基)N-苯甲酰基-1,2,3,4-四氢-β-咔啉的制备
在50ml圆底烧瓶中加入100mg(0.348mmol)1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉、20ml四氢呋喃、48μl三乙胺,然后滴加40μl苯甲酰氯,氮气保护下室温搅拌2小时,TLC显示原料反应完全。停止反应,加入20ml乙酸乙酯,用水洗(20ml×1),饱和氯化钠水溶液(20ml×1)洗涤,有机相用无水硫酸镁干燥过夜,过滤,蒸干滤液。经硅胶柱层析纯化,洗脱剂为石油醚∶乙酸乙酯=2∶1,得50mg淡红色粘稠液体,收率:36.8%。1HNMR(CDCl3)δ(ppm):2.76(m,1H,Carboline-C4-H),2.91(m,1H,Carboline-C4-H),2.49(m,1H,Carboline-C3-H),3.75(m,1H,Carboline-C3-H),6.92(s,1H,Carboline-C1-H),7.01-7.73(m,14H,Ar-H),8.18(br-s,1H,NH),8.34(br-s,1H,NH).MS(ESI)m/z(M-1)390.1.
实施例2:合成化合物2,1-(3-吲哚基)-2-邻氯苯甲酰基-1,2,3,4-四氢-β-咔啉
1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉与邻氯苯甲酰氯反应,合成过程同1。收率:27.0%。1HNMR(CDCl3)δ(ppm):2.76(m,1H,Carboline-C4-H),3.12(m,1H,Carboline-C4-H),3.48(m,2H,Carboline-C3-H),6.88-7.75(m,14H,Ar-H),8.09-8.33(m,2H,NH).MS(ESI)m/z(M-1)424.1.
实施例3:合成化合物3,1-(3-吲哚基)-2-对氯苯甲酰基-1,2,3,4-四氢-β-咔啉
1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉与对氯苯甲酰氯反应,合成过程同1。收率:60.8%。1HNMR(DMSO-d6)δ(ppm):2.71-2.85(m,2H,Carboline-C4-H),3.40(m,1H,Carboline-C3-H),3.55(m,1H,Carboline-C3-H),6.88(s,1H,Carboline-C1-H),6.95-7.03(m,2H,Indole-C6’-H+Carboline-C7-H),7.05-7.12(m,2H,Indole-C5’-H+Carboline-C6-H),7.20(s,1H,Indole-C2’-H),7.28(d,1H,Indole-C7’-H,J=7.8Hz),7.34-7.40(m,3H,Ar-H+Carboline-C8-H),7.44-7.52(m,3H,Ar-H+Carboline-C5-H),7.63(d,1H,Indole-C4’-H,J=7.8 Hz),11.05-11.10(m,2H,NH).MS(ESI)m/z(M-1)424.1.
实施例4:合成化合物4,1-(3-吲哚基)-2-对硝基苯甲酰基-1,2,3,4-四氢-β-咔啉
1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉与对硝基苯甲酰氯反应,合成过程同1。收率:收率:17.5%。1HNMR(CDCl3):2.81-2.95(m,2H,Carboline-C4-H),3.59(m,2H,Carboline-C3-H),7.01(s,1H,Carboline-C1-H),7.11(t,1H,Indole-C6’-H,J1=7.8Hz,J2=7.0Hz),7.08-7.58(m,7H,Ar-H),7.76(d,1H,Indole-C4’-H,J=7.8 Hz),8.01(br-s,1H,NH),8.20(br-s,1H,NH),8.18-8.32(m,4H,Ar-H).MS(ESI)m/z(M-1)435.1.
实施例5:合成化合物5,1-(3-吲哚基)-2-对甲氧基苯甲酰基-1,2,3,4-四氢-β-咔啉
1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉与对甲氧基苯甲酰氯反应,合成过程同1。收率:18.2%。1HNMR(CDCl3):2.95(m,1H,Carboline-C4-H),3.11(m,1H,Carboline-C4-H),3.48(m,1H,Carboline-C3-H),3.70(m,1H,Carboline-C3-H),3.81(d,2H,OCH3-H),6.76-8.05(m,14H,Ar-H),8.14-8.26(m,2H,NH).MS(ESI)m/z(M-1)420.2.
实施例6:合成化合物6,1-(3-吲哚基)-2-(3-吲哚基)甲酰基-1,2,3,4-四氢-β-咔啉
1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉与3-吲哚甲酰氯反应,合成过程同1。收率:收率:17.8%。1HNMR(DMSO-d6):2.82(m,2H,Carboline-C4-H),3.45(m,1H,Carboline-C3-H),4.25(m,1H,Carboline-C3-H),6.85(s,1H,Carboline-C1-H),6.86-7.50(m,13H,Ar-H),7.69(d,1H,Ar-H,J=3.1 Hz),11.03(m,2H,NH),11.56(br-s,1H,NH).
实施例7:合成化合物7,1-(3-吲哚基)-2-(3-吡啶基)甲酰基-1,2,3,4-四氢-β-咔啉
1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉与3-吡啶甲酰氯反应,合成过程同1。收率:收率:14.7%。1HNMR(CDCl3):2.83-3.04(m,2H,Carboline-C4-H),3.56-3.80(m,2H,Carboline-C3-H),7.06(s,1H,Carboline-C1-H),7.08-7.80(m,9H,Ar-H),7.91(s,1H,Indole-C2’-H),7.94(br-s,1H,NH),8.12(tt,1H,Ar-H),8.17(br-s,1H,NH),8.32-8.36(m,2H,Ar-H).MS(ESI)m/z(M-1)391.1.
实施例8:合成化合物8,1-(3-吲哚基)-2-(4-吡啶基)甲酰基-1,2,3,4-四氢-β-咔啉
1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉与4-吡啶甲酰氯反应,合成过程同1。收率:24.5%。1HNMR(DMSO-d6):2.76(m,1H,Carboline-C4-H),2.86(m,1H,Carboline-C4-H),3.44(m,2H,Carboline-C3-H),6.89(s,1H,Carboline-C1-H),6.97-7.13(m,4H,Ar-H),7.20(s,1H,Indole-C2’-H),7.27-7.39(m,4H,Ar-H),7.46(d,1H,Ar-H,J=7.8Hz),7.63(d,1H,Ar-H,J=7.8Hz),8.64(d,2H,Ar-H,J=5.5Hz),11.06(s,1H,NH),11.11(s,1H,NH).MS(ESI)m/z(M-1)391.1.
实施例9:合成化合物9,1-(3-吲哚基)-2-(2-吡啶基)甲酰基-1,2,3,4-四氢-β-咔啉
1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉与2-吡啶甲酰氯反应,合成过程同1。收率:19.6%。1HNMR(CDCl3):2.76(m,1H,Carboline-C4-H),3.11(m,1H,Carboline-C4-H),3.52(m,1H,Carboline-C3-H),3.95(m,1H,Carboline-C3-H),6.91(s,1H,Carboline-C1-H),7.02(t,1H,Indole-C6’-H,J1=7.8Hz,J2=7.0Hz),7.11-7.80(m,11H,Ar-H),8.05(br-s,1H,NH),8.40(br-s,1H,NH),8.56(d,1H,Ar-H).MS(ESI)m/z(M-1)391.1.
实施例10:合成化合物10,1-(3-吲哚基)-2-苯乙酰基-1,2,3,4-四氢-β-咔啉
1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉与苯乙酰氯反应,合成过程同1。收率:28.4%。1HNMR(DMSO-d6):2.57(m,1H,Carboline-C4-H),2.70(m,1H,Carboline-C4-H),3.34(m,1H,Carboline-C3-H),3.83(s,2H,COCH2),4.03(m,1H,Carboline-C3-H),6.77(s,1H,Carboline-C1-H),6.91-7.10(m,4H,Ar-H),7.14(s,1H,Indole-C2’-H),7.16-7.26(m,6H,Ar-H),7.34(d,1H,Ar-H,J=8.6Hz),7.40(d,1H,Ar-H,J=7.8Hz),7.60(d,1H,Ar-H,J=7.8Hz),10.96(s,1H,NH),11.02(s,1H,NH).MS(ESI)m/z(M-1)404.2.
实施例11:合成化合物11,1-(3-吲哚基)-2-苯丙酰基-1,2,3,4-四氢-β-咔啉
1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉与苯丙酰氯反应,合成过程同1。收率:22.8%。1HNMR(DMSO-d6):2.64-2.92(m,6H,CH2+Carboline-C4-H),3.31(m,1H,Carboline-C3-H),3.95(m,1H,Carboline-C3-H),6.78(s,1H,Carboline-C1-H),6.91-7.26(m,11H,Ar-H),7.34(d,1H,Ar-H,J=7.8Hz),7.43(d,1H,Ar-H,J=7.0Hz),7.58(d,1H,Ar-H,J=7.8Hz),10.93(br-s,1H,NH),10.99(br-s,1H,NH).MS(ESI)m/z(M-1)418.2.
实施例12:合成化合物12,1-(3-吲哚基)-2-肉桂酰基-1,2,3,4-四氢-β-咔啉
1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉与肉桂酰氯反应,合成过程同1。收率:22.9%。1HNMR(DMSO-d6):2.85(m,2H,Carboline-C4-H),3.44(m,1H,Carboline-C3-H),4.40(m,1H,Carboline-C3-H),6.85(s,1H,Carboline-C1-H),6.93-7.09(m,4H,Ar-H),7.25-7.75(d,12H,Ar-H),10.99(br-s,1H,NH),11.03(br-s,1H,NH).MS(ESI)m/z(M-1)416.1.
实施例13:合成化合物13,1-(3-吲哚基)-2-甲磺酰基-1,2,3,4-四氢-β-咔啉
1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉与甲烷磺酰氯反应,合成过程同1。收率:20.9%。1HNMR(CDCl3):2.57(s,3H,SO2CH3),2.84(m,1H,Carboline-C4-H),3.04(m,1H,Carboline-C4-H),3.37(m,1H,Carboline-C3-H),3.94(m,1H,Carboline-C3-H),6.39(s,1H,Carboline-C1-H),6.75(s,1H,Indole-C2’-H),7.03-7.34(m,6H,Ar-H),7.57(d,1H,Ar-H,J=7.0Hz),7.77-7.83(m,2H,Ar-H+NH),8.21(br-s,1H,NH).MS(ESI)m/z(M-1)364.1.
实施例14:合成化合物14,1-(3-吲哚基)-2-对甲苯磺酰基-1,2,3,4-四氢-β-咔啉
1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉与对甲苯磺酰氯反应,合成过程同1。收率:21.7%。1HNMR(CDCl3):2.21(s,3H,CH3),2.57(m,2H,Carboline-C4-H),3.40(m,1H,Carboline-C3-H),3.91(m,1H,Carboline-C3-H),6.64(s,1H,Carboline-C1-H),6.75(s,1H,Indole-C2’-H),6.94-7.40(m,9H,Ar-H),7.55(d,2H,Ar-H,J=7.8Hz),7.72(br-s,1H,NH),7.76(m,1H,Ar-H),8.06(br-s,1H,NH).MS(ESI)m/z(M-1)440.1.
实施例15:合成化合物15,1-(3-吲哚基)-2-乙基-1,2,3,4-四氢-β-咔啉将150mg(0.52mmol)1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉和10ml DMF投入50ml茄型瓶中,加入39μl(0.41mmol)溴乙烷、72mg碳酸钾和少量碘化钾作催化剂,室温搅拌24小时,TLC跟踪原料反应完全。停止反应,加入30ml乙酸乙酯,依次用水(15ml×2),饱和氯化钠水溶液(15ml×1)洗涤,无水硫酸镁干燥,过滤,蒸干滤液。残余物经硅胶柱层析纯化,洗脱剂为石油醚∶乙酸乙酯=2∶1,得40mg粘稠液体,收率:24.2%。1HNMR(CDCl3):1.11(t,3H,CH3,J=7.0Hz),2.55(m,1H,Carboline-C4-H),2.84(m,2H,Carboline-C4-H+Carboline-C3-H),2.97(m,2H,CH2),3.38(m,1H,Carboline-C3-H),5.10(s,1H,Carboline-C1-H),6.99-7.22(m,6H,Ar-H),7.35(d,1H,Ar-H,J=7.8Hz),7.55(m,3H,Ar-H+NH),8.52(br-s,1H,NH).MS(ESI)m/z(M-1)316.1.
实施例16:合成化合物16,1-(3-吲哚基)-2-正丙基-1,2,3,4-四氢-β-咔啉1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉与1-碘代正丙烷反应,合成过程同15。收率:34.9%。1HNMR(CDCl3):0.79(t,3H,CH3,J=7.4Hz),1.57(m,2H,CH2),2.41(m,1H,Carboline-C4-H),2.65-2.78(m,2H,Carboline-C4-H+Carboline-C3-H),2.94(m,2H,CH2),3.37(m,1H,Carboline-C3-H),4.98(s,1H,Carboline-C1-H),7.02-7.21(m,6H,Ar-H),7.34(d,1H,Ar-H,J=7.8Hz),7.40(br-s,1H,NH),7.55(m,1H,Ar-H),7.61(d,1H,Ar-H,J=8.2Hz),8.16(br-s,1H,NH).MS(ESI)m/z(M-1)328.2.
实施例17:合成化合物17,1-(3-吲哚基)-2-正丁基-1,2,3,4-四氢-β-咔啉1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉与1-碘代正丁烷反应,合成过程同15。收率:22.3%。1HNMR(CDCl3):0.81(t,3H,CH3,J=7.4Hz),1.22(m,2H,CH2),1.54(m,2H,CH2),2.43(m,1H,Carboline-C4-H),2.70-2.80(m,2H,Carboline-C4-H+Carboline-C3-H),2.94(m,2H,CH2),3.38(m,1H,Carboline-C3-H),4.98(s,1H,Carboline-C1-H),7.02-7.21(m,6H,Ar-H),7.34(d,1H,Ar-H,J=8.2 Hz),7.41(br-s,1H,NH),7.50-7.61(m,2H,Ar-H),8.19(br-s,1H,NH).MS(ESI)m/z(M-1)342.2.
实施例18:合成化合物18,1-(3-吲哚基)-2-正庚基-1,2,3,4-四氢-β-咔啉1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉与1-溴代正庚烷反应,合成过程同15。收率:20.0%。1HNMR(CDCl3):0.83(t,3H,CH3,J=7.4Hz),1.08-1.22(m,6H,CH2),1.53(m,2H,CH2),1.66(m,2H,CH2),2.40(m,1H,Carboline-C4-H),2.68-2.78(m,2H,Carboline-C4-H+Carboline-C3-H),2.93(m,2H,CH2),3.37(m,1H,Carboline-C3-H),4.97(s,1H,Carboline-C1-H),7.02-7.20(m,6H,Ar-H),7.36(d,1H,Ar-H,J=8.2 Hz),7.41(br-s,1H,NH),7.52-7.61(m,2H,Ar-H),8.14(br-s,1H,NH).MS(ESI)m/z(M-1)384.2.
实施例19:合成化合物19,1-(3-吲哚基)-2-正辛基-1,2,3,4-四氢-β-咔啉1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉与1-溴代正辛烷反应,合成过程同15。收率:33.7%。1HNMR(CDCl3):0.85(t,3H,CH3,J=7.4Hz),1.16(m,8H,CH2),1.53(m,2H,CH2),1.62(m,2H,CH2),2.40(m,1H,Carboline-C4-H),2.68-2.78(m,2H,Carboline-C4-H+Carboline-C3-H),2.93(m,2H,CH2),3.37(m,1H,Carboline-C3-H),4.97(s,1H,Carboline-C1-H),7.02-7.20(m,6H,Ar-H),7.36(d,1H,Ar-H,J=8.2 Hz),7.41(br-s,1H,NH),7.52-7.61(m,2H,Ar-H),8.14(br-s,1H,NH).MS(ESI)m/z(M-1)398.2.
实施例20:合成化合物20,1-(3-吲哚基)-2-正十二烷基-1,2,3,4-四氢-β-咔啉
1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉与1-溴代正十二烷反应,合成过程同15。收率:10.6%。1HNMR(CDCl3):0.89(t,3H,CH3,J=7.0Hz),1.14-1.28(m,8H,CH2),1.55(m,2H,CH2),2.41(m,1H,Carboline-C4-H),2.74(m,2H,Carboline-C4-H+Carboline-C3-H),2.94(m,2H,CH2),3.37(m,1H,Carboline-C3-H),4.97(s,1H,Carboline-C1-H),7.02-7.20(m,6H,Ar-H),7.34(d,1H,Ar-H,J=8.2 Hz),7.40(br-s,1H,NH),7.52-7.62(m,2H,Ar-H),8.14(br-s,1H,NH).MS(ESI)m/z(M-1)454.3.
实施例21:合成化合物21,1-(3-吲哚基)-2-苄基-1,2,3,4-四氢-β-咔啉1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉与氯苄反应,合成过程同15。收率:20.3%。1HNMR(CDCl3):2.68(m,1H,Carboline-C4-H),2.84(m,1H,Carboline-C4-H),2.96(m,1H,Carboline-C3-H),3.30(m,1H,Carboline-C3-H),3.40(d,1H,CH2,J=13.7Hz),4.04(d,1H,CH2,J=13.3Hz),5.02(s,1H,Carboline-C1-H),7.02-7.38(m,12H,Ar-H),7.42(br-s,1H,NH),7.52-7.64(m,2H,Ar-H),8.09(br-s,1H,NH).MS(ESI)m/z(M-1)376.2.
实施例22:合成化合物22,1-(3-吲哚基)-2-(5-(2-甲酰基)呋喃)亚甲基-1,2,3,4-四氢-β-咔啉
1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉与5-氯甲基呋喃-2-甲醛反应,合成过程同15。收率:19.4%。1HNMR(CDCl3):2.87(m,2H,Carboline-C4-H),3.08(m,1H,Carboline-C3-H),3.37(m,1H,Carboline-C3-H),3.76(d,1H,CH2,J=15.6 Hz),3.94(d,1H,CH2,J=15.6 Hz),5.05(s,1H,Carboline-C1-H),6.39(d,1H,Furan-H,J=3.1Hz),6.98-7.20(m,6H,Ar-H),7.27(d,1H,Furan-H,J=2.3 Hz),7.3 5(d,1H,Ar-H,J=8.6 Hz),7.43(br-s,1H,NH),7.52(m,2H,Ar-H),8.29(br-s,1H,NH),9.52(s,1H,CHO).MS(ESI)m/z(M-1)372.2.
实施例23:合成化合物23,1-(3-吲哚基)-2-乙氧羰基亚甲基-1,2,3,4-四氢-β-咔啉
1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉与溴乙酸乙酯反应,合成过程同15。收率:20.5%。1HNMR(CDCl3):1.22(t,3H,CH3,J=7.0Hz),2.90(m,1H,Carboline-C4-H),3.08(m,1H,Carboline-C4-H),3.19(m,1H,Carboline-C3-H),3.34(m,1H,Carboline-C3-H),3.44(q,2H,CH2,J=16.8 Hz),4.11(q,2H,CH2,J=7.0 Hz),5.43(s,1H,Carboline-C1-H),6.98-7.19(m,6H,Ar-H),7.34(d,1H,Ar-H,J=8.2 Hz),7.45(br-s,1H,NH),7.54-7.58(m,2H,Ar-H),8.27(br-s,1H,NH).MS(ESI)m/z(M-1)372.2.
实施例24:合成化合物24,1-(3-吲哚基)-2-乙氧羰基丙基-1,2,3,4-四氢-β-咔啉
1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉与溴乙酸乙酯反应,合成过程同15。收率:20.5%。1HNMR(CDCl3):1.17(t,3H,CH3,J=7.0Hz),1.84(m,2H,CH2),2.10-2.28(m,2H,CH2),2.43(m,1H,Carboline-C4-H),2.73(m,2H,Carboline-C4-H+Carboline-C3-H),2.95(m,2H,CH2),3.38(m,1H,Carboline-C3-H),3.99(m,2H,CH2),4.91(s,1H,Carboline-C1-H),6.98-7.20(m,6H,Ar-H),7.31(d,1H,Ar-H,J=7.8 Hz),7.43(br-s,1H,NH),7.55(m,2H,Ar-H),8.27(br-s,1H,NH).MS(ESI)m/z(M-1)372.2.
实施例25:稻瘟霉菌活性测试
采用宕崎成夫教授等建立的以稻瘟霉(Pyricularia oryzae)分生孢子变形、菌丝生长形态变异或抑制萌发为指标的生物活性检测方法,用于寻找抗真菌的活性成分。具体的活性指标的确定标准分为:抑制活性(抑制孢子的萌发,孢子基本保持原有形态)、强活性(孢子不萌发,或萌发,或菌丝生长,但形态都发生严重变化)、变形活性(孢子萌发或菌丝生长,但形态发生中等强度的变化)、弱变形活性(菌丝生长,但生长状态异常)和无活性(菌丝生长正常)。
所涉及的实验试剂及仪器:
稻瘟霉P-2b菌株,东京大学分子细胞生物学研究所提供。培养基为50%海水马铃薯葡萄糖培养基(1/2 PD)。倒置显微镜为上海光学仪器六厂产品。
将稻瘟霉P-2b菌株接种于斜面培养基(含酵母提取物0.2%,可溶性淀粉1%,琼脂2%),在27℃培养12~14d,用适量无菌水刮取孢子,过滤除去菌丝,得到孢子悬浮液,然后加入2%酵母提取物,并用无菌水调节使得最终孢子浓度为4×104个/mL,孢子悬浮液中酵母提取物的浓度为0.02%。活性检测利用96孔细胞培养板进行。检测使用灰黄霉素(Griseofulvin)作为阳性对照物,96孔板的每一列测试一个样品,每个样品测试八个浓度,加好样的96孔板在27℃培养16h,然后用倒置显微镜观察孢子生长和菌丝变形的情况,以目标化合物不再抑制稻瘟霉生长作为判断终点,得到最小抑制浓度(MIC)。
实施例26:体外抗肿瘤细胞活性测试
筛选方法采用四氮唑盐(microculture tetrozolium,MTT)还原法。MTT分析法以代谢还原3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide(MTT)为基础。活细胞的线粒体中存在与NADP相关的脱氢酶,可将黄色的MTT还原为不溶性的蓝紫色的甲月替(Formazan),死细胞此酶消失,MTT不被还原。用DMSO溶解Formazan后用酶标仪在570nm波长处检测光密度。
所用实验材料与试剂,其中RPMI1640培养基购自Gibco公司;四氮唑盐(MTT)购自上海源聚生物科技有限公司;酶标仪为Elx 800(Bio-tek InstrumentInc.);Caco-2结肠癌肿瘤细胞(国家新药筛选中心)。
采用96孔平板作微培养筛选,用MTT方法观察细胞的杀伤或生长抑制。对每个细胞株,每个浓度均为三个复孔。根据受试药物的细胞毒作用具有的亚板块特异性,鉴别具有选择性的抗肿瘤药物。用酶标仪测OD570值。
按下列公式计算被测物对癌细胞生长的抑制率。
并以化合物浓度的对数和抑制率作回归方程,计算IC50,表明大多数化合物有抗肿瘤活性。
表1是本发明化合物的抗稻瘟霉菌活性测试结果和抗肿瘤细胞活性结果。
表1
结果表明,本发明中大多数和化合物均显示出较好的抗稻瘟霉菌和抗肿瘤细胞(Caco-2结肠癌细胞)的活性。
Claims (31)
5、根据权利要求1所述的1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉衍生物,其特征是具有下述结构的化合物4,
10、根据权利要求1所述的1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉衍生物,其特征是具有下述结构的化合物9,
17、根据权利要求1所述的1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉衍生物,其特征是具有下述结构的化合物16,
24、根据权利要求1所述的1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉衍生物,其特征是具有下述结构的化合物23,
26、据权利要求1或2-15所述的1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉衍生物的制备方法,其特征是采用吲哚为原料经酰化得吲哚-3-甲醛,与色胺经缩合、环合得到1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与各种酰氯酰化后得到相应的化合物。
27、据权利要求1或16-25所述的1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉衍生物的制备方法,其特征是采用吲哚为原料经酰化得吲哚-3-甲醛,与色胺经缩合、环合得到1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉,与各种卤代物烃化后得到相应的化合物。
28、权利要求1的1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉衍生物在制备抗稻瘟霉菌药物中的用途。
29、据权利要求1的1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉衍生物在制备抗真菌药物中的用途。
30、据权利要求1的1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉衍生物在制备抗肿瘤药物中的用途。
31、据权利要求1的1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉衍生物在制备抗Caco-2结肠癌药物中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200710038006 CN101020688A (zh) | 2007-03-12 | 2007-03-12 | 1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉衍生物、制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200710038006 CN101020688A (zh) | 2007-03-12 | 2007-03-12 | 1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉衍生物、制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101020688A true CN101020688A (zh) | 2007-08-22 |
Family
ID=38708575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200710038006 Pending CN101020688A (zh) | 2007-03-12 | 2007-03-12 | 1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉衍生物、制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101020688A (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2214485A1 (en) * | 2007-09-25 | 2010-08-11 | Minerva Biotechnologies Corp. | Methods for treatment of cancer |
WO2015101206A1 (zh) | 2013-12-30 | 2015-07-09 | 南开大学 | β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用 |
CN105481855A (zh) * | 2015-12-22 | 2016-04-13 | 西北农林科技大学 | β-咔啉类化合物及其合成方法、以及含有该化合物的药物及应用 |
CN107880040A (zh) * | 2017-12-22 | 2018-04-06 | 中国药科大学 | 一种四氢β-咔啉类衍生物及其制备方法与用途 |
US11202775B2 (en) | 2007-09-25 | 2021-12-21 | Minerva Biotechnologies Corporation | Methods for treatment of cancer |
-
2007
- 2007-03-12 CN CN 200710038006 patent/CN101020688A/zh active Pending
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2214485A1 (en) * | 2007-09-25 | 2010-08-11 | Minerva Biotechnologies Corp. | Methods for treatment of cancer |
EP2214485A4 (en) * | 2007-09-25 | 2012-01-11 | Minerva Biotechnologies Corp | METHOD FOR THE TREATMENT OF CANCER |
US11202775B2 (en) | 2007-09-25 | 2021-12-21 | Minerva Biotechnologies Corporation | Methods for treatment of cancer |
WO2015101206A1 (zh) | 2013-12-30 | 2015-07-09 | 南开大学 | β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用 |
US10208033B2 (en) | 2013-12-30 | 2019-02-19 | Nankai University | β-carboline, dihydro-β-carboline and tetrahydro-β-carboline alkaloid derivatives and preparation methods same and use in aspects of preventing and treating plant viruses, fungicides and insecticides |
EP3459950A1 (en) | 2013-12-30 | 2019-03-27 | Nankai University | Beta-carboline, dihydro-beta-carboline and tetrahydro-beta-carboline alkaloid derivatives, method for preparing the same and use in aspects of preventing and treating plant viruses, as fungicides and insecticides |
EP3459951A1 (en) | 2013-12-30 | 2019-03-27 | Nankai University | Beta-carboline, dihydro-beta-carboline and tetrahydro-beta-carboline alkaloid derivatives, method for preparing the same and use in aspects of preventing and treating plant viruses, as fungicides and insecticides |
CN105481855A (zh) * | 2015-12-22 | 2016-04-13 | 西北农林科技大学 | β-咔啉类化合物及其合成方法、以及含有该化合物的药物及应用 |
CN105481855B (zh) * | 2015-12-22 | 2018-02-06 | 西北农林科技大学 | β‑咔啉类化合物及其合成方法、以及含有该化合物的药物及应用 |
CN107880040A (zh) * | 2017-12-22 | 2018-04-06 | 中国药科大学 | 一种四氢β-咔啉类衍生物及其制备方法与用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vatmurge et al. | Synthesis and biological evaluation of bile acid dimers linked with 1, 2, 3-triazole and bis-β-lactam | |
US20230061083A1 (en) | Kras g12c inhibitor compound and use thereof | |
SE441830B (sv) | Forfarande for framstellning av maytansinoider | |
DK166881B1 (da) | 1,5-benzoxazepinforbindelser, farmaceutisk praeparat indeholdende dem samt forbindelserne og praeparatet til anvendelse ved terapeutisk behandling af pattedyr | |
JPH01168689A (ja) | K−252誘導体 | |
KR20120139763A (ko) | 랄테그라비어 염 및 이의 결정형 | |
CN103038218B (zh) | 稠环吡啶化合物 | |
CN101020688A (zh) | 1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉衍生物、制备方法和用途 | |
WO2019154395A1 (zh) | 四氢异喹啉类化合物、其制备方法、包含此类化合物的药物组合物及其用途 | |
CN114751891B (zh) | 一种(2-(1h-吲哚-3-基)-1h-咪唑-4-基)苯基甲酮类化合物及其应用 | |
CA2100682A1 (en) | Indoles useful as platelet activating factor antagonists | |
CN101020689A (zh) | 1-(3-吲哚基)-6,7-亚甲二氧基-1,2,3,4-四氢异喹啉衍生物、制备方法和用途 | |
CN110551102A (zh) | Alk共价抑制剂及其用途 | |
CN109796468B (zh) | 大环nannocystin衍生物、及其制备方法和用途 | |
US7317100B2 (en) | Epothilone derivatives | |
KR900006234B1 (ko) | 신규의 3', 4'-디니트로겐 치환 에피포도필로톡신 배당체의 유도체 | |
CN112824415A (zh) | 一种氧氟沙星的丙烯酮衍生物及其制备方法和应用 | |
CN111303189A (zh) | 一种芦氟沙星的丙烯酮衍生物及其制备方法和应用 | |
CN111303027A (zh) | 一种氟罗沙星的丙烯酮衍生物及其制备方法和应用 | |
CN114478403B (zh) | 一种含芳香胍基类化合物及其制备方法与应用 | |
CN115536567A (zh) | 含有光亲和基团双吖丙啶的β-榄香烯衍生物及其制备方法和作为光亲和分子探针的应用 | |
JP7118354B2 (ja) | 三環式化合物の結晶形及びその使用 | |
EP3241823B1 (en) | Pyrrole amide compound, preparation method therefor, and use thereof | |
CN112824396B (zh) | 一种n-乙酰基洛美沙星的丙烯酮衍生物及其制备方法和应用 | |
WO2022134262A1 (zh) | 二吡咯甲烯-1-酮类化合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |